header advert
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

A THREE-YEAR PROSPECTIVE FOLLOW-UP OF THE CPS-PLUS STEM – HOW TO PLEASE THE NICE GUYS



Abstract

Introduction: The CPS-Plus cemented, collarless, polished stem, is a double-taper design with rectangular cross section. An additional proximal stem centraliser ensures optimal alignment of the stem and an even cement mantle and has been shown to increase cement pressurisation during insertion.

Guidelines from the National Institute of Clinical Excellence (NICE) recommend comparative clinical evaluation for prostheses without long-term follow-up data and set an initial ‘benchmark’ for performance at 3 years.

Data collection for the CPS-Plus stem is on-going as part of a multi-centre prospective clinical trial. 227 patients have been recruited to the trial and 70 of these have reached 3 years follow-up.

Method: Patients were recruited to the study by surgeons working at three centres in the UK and two in Norway. Patients were fully evaluated pre-operatively. Operative details, post-operative course and follow-up visits at 3, 6, 12, 24, and 36 months were recorded. Postoperative clinical progress was monitored using recognised scoring systems and radiographic assessment.

Results: The mean Harris hip score (0 – 100) improved from 42.7 pre-op to 91.6 at 6 months and 95.8 at 3 years. The mean Merle d’Aubigne and Postel score (0 – 18) improved from 8.55 pre-op to 16.09 at 6 months and 17.08 at 3 years. The mean Oxford hip score (60 – 12) improved from 41.6 pre-op to 14.1 at 3 years. Radiological subsidence at 3 years is less that 1.5mm in 97% of patients and less than 3mm in the remainder. From all 227 implants, there has been one revision for deep infection. There have been no cases of aseptic loosening. Other significant complications include one peri-prosthetic fracture and 4 dislocations, but these were not thought to be related to the design of the implant.

Discussion: The early results of the CPS-Plus femoral stem are encouraging and the prosthesis achieves the 3-year benchmark set out in the NICE guidelines, with a zero revision rate in the first 70 patients recruited to the trial. The prosthesis shares many design features with other well-established collarless, polished, tapered stems. The ease of accurate insertion and improved cement pressurisation resulting from its unique design features should ensure excellent medium to long-term outcome. The multi-centre clinical trial will continue to monitor progress.

Theses abstracts were prepared by Mr Peter Kay. Correspondence should be address to him at The Hip Centre, Wrightington Hospital, Appley Bridge, Wigan, Lancashire WN6 9EP.